jaguar health, inc. is a commercial stage natural-products pharmaceuticals company focused on developing novel, sustainably derived gastrointestinal products for both human prescription use and animals on a global basis. our wholly-owned subsidiary, napo pharmaceuticals, inc., focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas. our mytesi® (crofelemer) product is approved by the u.s. fda for the symptomatic relief of noninfectious diarrhea in adults with hiv/aids on antiretroviral therapy. canalevia™ is our lead animal prescription drug candidate, intended for treatment of various forms of diarrhea in dogs. equilevia™ is jaguar’s non-prescription product for total gut health in equine athletes. to read our full social media policy, please visit https://jaguar.health/social-media-policy/
Company profile
Ticker
JAGX
Exchange
Website
CEO
Lisa Conte
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Jaguar Animal Health, Inc.
SEC CIK
Corporate docs
Subsidiaries
Napo Pharmaceuticals, Inc. ...
JAGX stock data
Latest filings (excl ownership)
DEFA14A
Additional proxy soliciting materials
31 May 24
ARS
2023 FY
Annual report to shareholders
28 May 24
8-K
Jaguar Health, Inc. Announces Reverse Stock Split
23 May 24
424B5
Prospectus supplement for primary offering
23 May 24
DEF 14A
Definitive proxy
21 May 24
10-Q
2024 Q1
Quarterly report
14 May 24
PRE 14A
Preliminary proxy
10 May 24
EFFECT
Notice of effectiveness
2 May 24
424B3
Prospectus supplement
1 May 24
S-3
Shelf registration
22 Apr 24
Transcripts
JAGX
Earnings call transcript
2024 Q1
14 May 24
JAGX
Earnings call transcript
2023 Q4
1 Apr 24
JAGX
Earnings call transcript
2023 Q3
14 Nov 23
JAGX
Earnings call transcript
2023 Q2
14 Aug 23
JAGX
Earnings call transcript
2023 Q2
14 Aug 23
JAGX
Earnings call transcript
2023 Q1
15 May 23
JAGX
Earnings call transcript
2022 Q4
27 Mar 23
JAGX
Earnings call transcript
2022 Q3
14 Nov 22
JAGX
Earnings call transcript
2022 Q2
22 Aug 22
JAGX
Earnings call transcript
2022 Q1
10 May 22
Latest ownership filings
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 11.67 mm | 11.67 mm | 11.67 mm | 11.67 mm | 11.67 mm | 11.67 mm |
Cash burn (monthly) | (no burn) | 224.67 k | 3.12 mm | 3.31 mm | 2.35 mm | 2.53 mm |
Cash used (since last report) | n/a | 486.05 k | 6.76 mm | 7.17 mm | 5.08 mm | 5.47 mm |
Cash remaining | n/a | 11.18 mm | 4.92 mm | 4.50 mm | 6.59 mm | 6.20 mm |
Runway (months of cash) | n/a | 49.8 | 1.6 | 1.4 | 2.8 | 2.5 |
Institutional ownership, Q4 2023
16.7% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 5 |
Opened positions | 0 |
Closed positions | 15 |
Increased positions | 1 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 3.15 bn |
Total shares | 48.98 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Nantucket Investments | 23.63 mm | $3.15 bn |
Streeterville Capital | 11.50 mm | $0.00 |
Iliad Research & Trading | 4.88 mm | $0.00 |
Oasis Capital | 4.60 mm | $0.00 |
Mailman Joshua | 4.37 mm | $0.00 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
17 May 24 | King Steven R. | Common Stock | Option exercise | Acquire M | No | No | 0 | 612 | 0.00 | 1,756 |
17 May 24 | King Steven R. | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 612 | 0.00 | 612 |
17 May 24 | Conte Lisa A | Common Stock | Option exercise | Acquire M | No | No | 0 | 2,695 | 0.00 | 7,295 |
17 May 24 | Conte Lisa A | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 2,695 | 0.00 | 2,694 |
17 May 24 | Lizak Carol R. | Common Stock | Option exercise | Acquire M | No | No | 0 | 431 | 0.00 | 1,042 |
17 May 24 | Lizak Carol R. | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 431 | 0.00 | 431 |
17 May 24 | Wolin Jonathan S. | Common Stock | Option exercise | Acquire M | No | No | 0 | 871 | 0.00 | 2,012 |
17 May 24 | Wolin Jonathan S. | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 871 | 0.00 | 871 |
17 May 24 | Pravin R Chaturvedi | Common Stock | Option exercise | Acquire M | No | No | 0 | 871 | 0.00 | 2,141 |
17 May 24 | Pravin R Chaturvedi | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 871 | 0.00 | 871 |
News
12 Health Care Stocks Moving In Thursday's Pre-Market Session
30 May 24
Jaguar Health And Magdalena Biosciences Executes Out-License Deal With For Botanical Drug Candidate for Schizophrenia
29 May 24
What's Going On With Jaguar Health Stock?
23 May 24
Dow Falls Over 150 Points; Sohu Posts Q1 Loss
20 May 24
Why Virios Therapeutics Shares Are Trading Lower By Around 48%? Here Are Other Stocks Moving In Monday's Mid-Day Session
20 May 24
Press releases
Nasdaq Stocks Soaring to the Top with Strategic Splits: NVDA, INBS, JAGX, SINT, GWAV
4 Jun 24
Jaguar Health Executes Out-License Deal with Joint Venture Magdalena Biosciences for Botanical Drug Candidate for Schizophrenia
29 May 24
Investigator-Initiated Trial of Jaguar Health's Crofelemer Yields Positive Results for Functional Diarrhea
28 May 24
Jaguar Health to Initiate Commercial Footprint in Cancer Supportive Care at American Society of Clinical Oncology (ASCO) Annual Meeting with Exhibit Booth for FDA-Approved Gelclair Oral Mucositis Product
23 May 24
Jaguar Health, Inc. Announces Reverse Stock Split
17 May 24